Methylphenidate in Pediatric Brain Tumor Survivors with Cancer-related Fatigue (EMBRAIN)

Odense University Hospital

Status and phase: Begins enrollment in 1 month; Phase 3

Conditions: Methylphenidate; Cancer-related Fatigue; Brain Tumor, Pediatric

Treatments: Drug: Placebo; Drug: Methylphenidate (MPH)

Study type: Interventional

Funder types: Other

Identifiers

NCT06905587

24/51848

2023-507926-18-00 (EU Trial (CTIS) Number)

2023-001094 (Other Grant/Funding Number)

R352-A20781 (Other Grant/Funding Number)

Details and patient eligibility

About

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

Enrollment: 50 estimated patients

Sex: All

Ages: 6 to 27 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
2. Treated for a PBT during the previous 10 years, starting from date of diagnosis.
3. Aged ≥6 years 0 months at the start of the trial.
4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
5. No known signs of clinical or radiological tumor progression at last follow-up.
6. Danish is the sole or primary language (enabling provision of validated assessment tools).
7. Patient and family have provided consent for inclusion in the trial.
8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion criteria

1. Any known contraindications to methylphenidate as outlined below:

   A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

2. History of recent poorly controlled seizures.

3. Motor tics or Tourette syndrome (including family history of tic disorder).

4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.

5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.

6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.

7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups

Methylphenidate, Then Placebo

Experimental group

Description:

Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

Treatment:

Drug: Methylphenidate (MPH)

Drug: Placebo

Placebo, Then Methylphenidate

Experimental group

Description:

Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

Treatment:

Drug: Methylphenidate (MPH)

Drug: Placebo